Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Lumos Pharma
Lumos Pharma
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)